2172

MicroPort NeuroScientific Corporation Stock Price

SEHK:2172 Community·HK$7.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

2172 Share Price Performance

HK$12.80
1.48 (13.07%)
HK$12.80
1.48 (13.07%)
Price HK$12.80

2172 Community Narratives

There are no narratives available yet.

Recent 2172 News & Updates

Optimistic Investors Push MicroPort NeuroScientific Corporation (HKG:2172) Shares Up 25% But Growth Is Lacking

Aug 10
Optimistic Investors Push MicroPort NeuroScientific Corporation (HKG:2172) Shares Up 25% But Growth Is Lacking

MicroPort NeuroScientific (HKG:2172) Could Be Struggling To Allocate Capital

Jul 29
MicroPort NeuroScientific (HKG:2172) Could Be Struggling To Allocate Capital

MicroPort NeuroScientific (HKG:2172) Will Pay A Dividend Of CN¥0.11

Jun 26
MicroPort NeuroScientific (HKG:2172) Will Pay A Dividend Of CN¥0.11

MicroPort NeuroScientific Corporation (HKG:2172) Looks Just Right With A 30% Price Jump

Jun 22
MicroPort NeuroScientific Corporation (HKG:2172) Looks Just Right With A 30% Price Jump

MicroPort NeuroScientific Corporation Key Details

CN¥736.5m

Revenue

CN¥194.5m

Cost of Revenue

CN¥541.9m

Gross Profit

CN¥338.3m

Other Expenses

CN¥203.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.35
Gross Margin
73.58%
Net Profit Margin
27.64%
Debt/Equity Ratio
0%

MicroPort NeuroScientific Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
2 Rewards

About 2172

Founded
2004
Employees
522
CEO
Zhiyong Xie
WebsiteView website
www.microportneurosci.com

MicroPort NeuroScientific Corporation provides neuro-interventional medical devices. The company offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk, a 3D electronically detachable coil; Numen Lighting, a coil embolization system; Numen Nest, a detachable coil; NuFairy absorbable coil embolization system; Tubridge, a flow-diverting stent; Tubridge Plus, a flow-diverting stent; WILLIS, a intracranial stent graft system; Comaneci, a embolization assist device; and Rebridge, an intracranial visualized stent for intracranial aneurysm, as well as liquid embolic agent for cerebral arteriovenous malformations. It also offers APOLLO intracranial stent system for intracranial atherosclerosis; Bridge rapamycin target eluting and Bridge MAX rapamycin target eluting vertebral artery stent system for vertebral artery stenosis; Diveer intracranial balloon dilatation catheter, intracranial drug-coated balloon catheter system, intracranial self-expanding rapamycin target eluting stent, and intracranial balloon-expandable rapamycin target eluting stent for intracranial stenosis; and Carotid stent system, Safecer embolic protection device, and PathFinder carotid balloon dilation catheter for carotid artery stenosis. In addition, the company provides NeuroHawk thrombectomy device, NeuroHawk pass17/21 and medibox thrombectomy device and accessories, Tigertriever revascularization device, WAVE-track intracranial aspiration catheter, X-track intracranial distal access catheter, and NeuroGuard neurovascular balloon guide catheter for acute ischemic stroke. Further, it offers U-track intracranial support catheter system, Fastrack microcatheter system, QUEEN-track and 17 Microcatheter, Veyronwire neurovascular guide wire, Sheathru delivery catheter, and filter extension tube for single use. The company was founded in 2004 and is headquartered in Shanghai, China. MicroPort NeuroScientific Corporation is a subsidiary of MicroPort Scientific Corporation.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Chinese Market Performance

  • 7 Days: 1.8%
  • 3 Months: 18.3%
  • 1 Year: 24.1%
  • Year to Date: 26.2%
The Industrials sector has led the market, which has gained 1.8%. As for the past 12 months, the market is up 24%. Looking forward, earnings are forecast to grow by 27% annually. Market details ›